Carta Genomics specializes in advanced genomic testing specifically designed for in-vitro fertilization (IVF), enabling prospective parents to assess the health risks associated with their embryos. The company employs a novel polygenic approach (PGT-P) that utilizes an advanced machine learning algorithm to analyze the interplay of multiple genes, allowing for the prediction of risks related to complex diseases. By examining the entire genome, which consists of approximately 3 billion base pairs, Carta combines hundreds of tests to provide couples with comprehensive insights into their embryos' health outcomes. This thorough analysis empowers parents to make informed decisions regarding embryo selection, ultimately aiming to enhance women's health and promote healthier future generations.

The testing services offered by Carta include PGT-A (Aneuploidy), PGT-SR (Structural), and PGT-M (Monogenic), each targeting different genetic conditions. PGT-P stands out as a new offering that assesses the risk of diseases influenced by multiple gene changes, such as breast cancer and type 2 diabetes. The process involves incubating embryos to the blastocyst stage, followed by DNA sequencing of a small cell sample from each embryo. The results are compiled into an easy-to-read report, detailing potential health risks for each embryo, thus facilitating the selection of the healthiest option for implantation. Carta's commitment to providing clinical-grade results and secure access to genomic data underscores its focus on patient-centered care in the realm of reproductive health.

United Kingdom

Carta provides advanced genomic testing for IVF. We help IVF parents predict their embryo's disease risk and health outcomes in advance, resulting in improved women's health and healthier babies.

Carta Genomics

Company Details